Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients
This study evaluate either Toripalimab or combined with chemotherapy as neoadjuvant treatment for patients with head and neck squamous cell carcinoma. Participants in arm A receive Toripalimab, in arm B receive Toripalimab plus PC (paclitaxel and carboplatin), arm C with Toripalimab plus modified TPF(paclitaxel and cisplatin and 5-fu).
Head and Neck Squamous Cell Carcinoma
DRUG: Toripalimab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: 5-fu
MPR, major pathologic response, 6 weeks
AE, adverse events, 2 years|RFS, recurrence free survival, 2 years|ORR, overall response rate, 6 weeks|PFS, progression free survival, 6 months
This study evaluate either Toripalimab or combined with chemotherapy as neoadjuvant treatment for patients with head and neck squamous cell carcinoma. Participants in arm A receive Toripalimab, in arm B receive Toripalimab plus PC (paclitaxel and carboplatin), arm C with Toripalimab plus modified TPF(paclitaxel and cisplatin and 5-fu).